Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, 100034, China.
Laboratory of Electron Microscopy, Pathological Centre, Peking University First Hospital, Beijing, 100034, China.
BMC Med. 2023 Feb 8;21(1):45. doi: 10.1186/s12916-023-02755-4.
The renal risk score (RRS) is a useful tool to predict end-stage renal disease (ESRD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The current study aimed to validate the predictive performance of RRS and to further modify this model in Chinese AAV patients.
Two hundred and seventy-two patients diagnosed with AAV confirmed by renal biopsies were retrospectively enrolled from a single center. The RRS was calculated based on 3 categorical variables, i.e., the proportion of normal glomeruli, the proportion of interstitial fibrosis and tubular atrophy (IF/TA), and eGFR at biopsy, classifying these patients into low-, medium-, and high-risk groups. In addition, a modified model was developed based on the RRS and was further validated in another independent cohort of 117 AAV patients. The predictive performance of each model was evaluated according to discrimination and calibration.
Patients were classified by the RRS into low- (26.5%), medium- (46.7%), and high-risk (26.8%) groups, with 120-month renal survival rates of 93.3%, 57.2%, and 18.4%, respectively (P < 0.001). The RRS showed good discrimination but less satisfactory calibration. Therefore, a modified model with improved discrimination and calibration was developed in Chinese AAV patients, with eGFR, proportion of normal glomeruli (both as continuous variables), and IF/TA (< 25%, 25-50%, > 50%) included. Internal and external validation of the modified model were performed. Finally, an online risk prediction tool was developed based on the modified model.
The RRS was an independent predictor of ESRD of AAV patients. The modified model could predict the probability of ESRD for AAV patients with improved performance in Chinese AAV patients.
肾风险评分(RRS)是一种预测抗中性粒细胞胞质抗体(ANCA)相关性血管炎(AAV)患者终末期肾脏疾病(ESRD)的有用工具。本研究旨在验证 RRS 的预测性能,并进一步对中国 AAV 患者的模型进行修正。
回顾性分析了一家单中心经肾活检确诊的 272 例 AAV 患者。根据 3 个分类变量,即正常肾小球比例、间质纤维化和肾小管萎缩(IF/TA)比例以及活检时的 eGFR,计算 RRS,将这些患者分为低、中、高危组。此外,还基于 RRS 建立了一个修正模型,并在另一个独立的 117 例 AAV 患者队列中进行了验证。根据判别和校准评估每个模型的预测性能。
根据 RRS,患者被分为低(26.5%)、中(46.7%)和高(26.8%)风险组,120 个月的肾脏生存率分别为 93.3%、57.2%和 18.4%(P < 0.001)。RRS 显示出良好的判别能力,但校准效果较差。因此,我们为中国 AAV 患者建立了一个修正模型,该模型具有更好的判别和校准效果,包括 eGFR、正常肾小球比例(均为连续变量)和 IF/TA(<25%、25-50%、>50%)。对修正模型进行了内部和外部验证。最后,基于修正模型开发了一个在线风险预测工具。
RRS 是 AAV 患者发生 ESRD 的独立预测因子。修正模型可预测中国 AAV 患者发生 ESRD 的概率,性能得到改善。